secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K/A
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001104659-22-112462
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva completes sale of 15% stake in Theravance Respiratory to Royalty Pharma for $281.9M upfront
--------------------------------------------------------------------------------

- Sold 750 Class A and 750 Class C Units (15% ownership) of TRC to Royalty Pharma Investments for $281.9M upfront.
- Upfront cash: $277.5M for equity plus $4.4M distribution of TRC cash.
- Eligible for $50M contingent sales-based milestone payment from buyer.
- Sale closed July 20, 2022; pro forma financials reflect disposition as if effective Jan 1, 2021.
- Pro forma condensed consolidated statements for six months ended June 30, 2022 and FY 2021 filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922112462/0001104659-22-112462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922112462/tm2229092d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-112462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer